TRIDHA
Journal of Clinical Cases & Reports
Volume 2021, Issue S13, 4 pages
https://doi.org/10.46619/joccr.2021.4-S13.1001

HYPOTHESIS

Can 5-Iodon-2'-Deoxyuridine Inhibit COVID-19?

Raghad S Mouhamad

Agricultural Research Directorate, Ministry of Science and Technology, Baghdad, Iraq

Correspondence should be addressed to Raghad S Mouhamad, raghad1974@yahoo.com

Received: 19 June 2021; Accepted: 10 July 2021; Published: 17 July 2021

HYPOTHESIS

Herpes labialis, classified as cold sores as well. Many patients are unable to deal with the central nervous system dysfunction that causes TLR3 cell receptors, which may contribute to child seizures and epilepsy. This disease is named simplex encephalitis or herpes. Lately, it was reported that all patients with COVID-19 have severe side effects. it was even discussed that one might even have a hereditary code that allows them to be more likely sensitive to coronavirus infections. TRIF adapter deficients were particularly vulnerable to SARS-CoV infection showing elevated weight loss, decreased lung capacity, elevated lung disease, higher viral titers, and more death rates. The most effective antiviral defence intrinsic host cell responses to extreme SARS-CoV diseases are expected to have a controlled immune response that is focused on TRIF-led or MyD88 pathways. The usage of vaccine adjuvants or antiviral substances was suggested as TLR agonists and antagonists.

THE QUESTION

The correlation between HIV virus and COVID-19 behaviour in immune response and cell receptors may be controlled with the same drug.

INTRODUCTION

In Wuhan - China, a new type of coronavirus has recently been identifies that trigger pneumonia-like symptoms and represented the start of the global disease expansion entitled COVID-19 later to be announce pandemic [1]. Coronaviruses (CoVs), are renowned for thesis "crown-like" s case, are a broad family of viruses transmitted from animals to humans and cause diseases such as the Middle Eastern Respiratory Syndrome (MERS) and SARS [2]. Extreme acute coronavirus 2 (SARS-CoV-2), formerly identified as the Latest Coronavirus in 2019 (2019-nCoV) is a single-stranded, positive sensor RNA that contributes to the potentially lifelike infection of the COVID-19 respiratory tract [3]. Coronaviruses include RNA genomes that enable the replication and modification in influenza viruses and those close to influenza [4]. Most animals invade the intestine or breath to induce diarrhea or airborne diseases. Saif notes that PEDV and PDCoV which first appeared in the US in 2013-14 and are still present in pigs are the best examples of coronaviruses that infect the gut and cause diarrhea

and deaths of pigs. Such viruses belong to two separate coronaviral types - alpha and delta [5]. The recurrent elevated nasopharyngeal viral RNA and viral RNA detection of blood and pleural fluids are often troubling in the case of a pandemic [6].

Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (I) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (II) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (III) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (IV) herpesvirus infections (5-substituted 2=-deoxy uridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (V) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (VI) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (VII) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2=-deoxy uridine analogues, and antibodies), (VIII) respiratory syncytial virus infections (ribavirin and antibodies), and (IX) external anogenital warts caused by human papillomavirus infections (imiquimod, sine catechins, and podofilox) [7]. 5-Iodon-2'-deoxyuridine (5-IUdR; IdUrd) is a drug with an antiviral function against the ortho-poxvirus pyrimidine analog (halogenated thymidine). Which was used in human cancer research IdUrd as a radiosensitizer [8]. The mechanism of IdUrds (AIdUrd, IdUrd and IdCyd) phosphorylation and eventual incorporation into viral RNA, the nuclear analogs IdUrds practice their antiviral effects [9]. For initial phosphorylation, AldUrd and IdCyd need herpesvirus pyrimidine deoxy riboside kinase, however IdUrd is both a viral and cellular phosphorylated kinase substratum [10]. The inclusion of viral RNA into the antiviral of these analogues represents a vital phenomenon; this incorporation contributes to a transformed distribution of viral RNA and protein species and to an irregular community of viruses with reduced basic infectivity that is able to interact with herpesvirus replication [11]. Varied pyrimidine deoxyribonucleosides were prepared and tested for in vitro Moloney-murine leukemia virus (M-MULV), the mammalian T-lymphotropic retrovirus, in a range of 3'-Zido (3'-Aminos), 2,3, '2',3'-Dideos and 5-substituted analogs [12]. The most successful ED50, ED50 values of 0.02 μm, 1.5 μm, 3.1 μm, 2,5 μm, 3.7 μm, and 4.0 μm were observed using thymidine 3'-azido analogues, 2'-deoxy-5- bromouridine, 2'-deoxy- 5 iodouridine analogs, 2,3'-unsaturated thymidine analog and 2'-deoxycytidine, and 2',3'-didaeoxycytytidine. In the host SC-1 cells up to 100 μm these active compounds are nontoxic. -2',3'-dideoxycytidine analogues [13,14]. The intensity of pyrimidine deiodination can be regulated both by pH shifts and by molecular combination of the nucleotide, which is bisulfite-catalyzed. The iodocytidine release a rate of polycytidylate iodine higher than the RNA removal limit. Experiments to check the impact of iodo pyrimidine base pairing in synthetic polynucleotides have shown that iodine bond is secured by pairing the replacement nucleotide. The levels of deiodination by bisulfite-catalyzed multiple RNAs have been calculated [15]. Bisulfite was evaluated in multi- on each of the single stranded RNAs, consisting of a fast early deiodination reaction, which was followed by a slower stage and then reactivated releases. By addition to the release from ribosomal and messenger RNA fragments, the release of iodine from duplexes of double strands RNA and DNA- was postponed [16]. The single and double sided RNA deiodination profiles showed that the

mid- iodine release is regulated by the melting of low - paired regions. Destabilizing the molecule by inserting bisulphites into the pyrimidine ring or slander will result in late release [17]. The interaction of polynucleotides of many compounds was found to be complicated. Acridine and bromide of orange and ethidium enhanced ribosomal RNA iodine loss and significantly diminished viral double stranded RNA disposal. Ribosomal RNA has been speeded up by a simple protein fraction derived from ribosomal particles. Although this protein fraction produced more destabilization than albumin in similar proportions, the effect measured is non-specific. The findings show that the development of chemical deiodination may be influenced by the contact with polynucleotides in limited amounts of protein [18]. The thymidine structural analog is idoxuridine or 5-iodo-2'-deoxyuridine: iodine that replaces a methylated component. Idoxuridine is incorporated in viral DNA and prevents the reproduction of the virus in host cells as it is transformed to triphosphate derivative rendering the viral RNA inactive. In certain nations, the herpes simplex virus keratitis has been used as an ophthalmic treatment [19,20].

REFERENCES

1. (2020) Wuhan City Health Committee. Wuhan Municipal Health and Health Commission's briefing on the current pneumonia epidemic situation in our city 2019.
2. Cascella M, Rajnik M, Aleem A et al. (2021) Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls.
3. Lai CC, Shih TP, Ko WC et al. (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents 55(3): 105924.
4. (2020) ICTV (International committee on the taxonomy of viruses) ICTV 9th report 2011.
5. Saif LJ (2004) Animal coronaviruses: Lessons for SARS. Learning from SARS: Preparing for the next disease outbreak. The National Academies Press, Washington, DC: 138-149.
6. Chen W, Lan Y, Yuan X et al. (2020) Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerging Microbes & Infections 9(1): 469-473.
7. De Clercq E and Li G (2016) Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews 29(3): 695-747.
8. Mitchell JB, Russo A, Cook JA et al. (1989) Radiobiology and clinical application of halogenated pyrimidine radiosensitizers. International Journal of Radiation Biology 56(5): 827-836.
9. Graci JD and Cameron CE (2008) Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virology 3(6): 553-566.
10. Keating JA and Striker R (2012) Phosphorylation events during viral infections provide potential therapeutic targets. Reviews in Medical Virology 22(3): 166-181.
11. Grinde B (2013) Herpesviruses: Latency and reactivation-viral strategies and host response. Journal of Oral Microbiology 5(1): 22766.
12. Mitsuya H and Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides. Proceedings of the National Academy of Sciences 83(6): 1911-1915.

13. Kofoed RH, Betzer C, Lykke-Andersen S et al. (2018) Investigation of RNA synthesis using 5-Bromouridine labelling and immunoprecipitation. Journal of Visualized Experiments: JoVE (135): e57056.
14. Perkins ES, Wood RM, Sears ML et al. (1962) Anti-viral activities of several iodinated pyrimidine deoxyribonucleosides. Nature 194(4832): 985-986.
15. Brossalina E, Demchenko E, Vlassov V (1991) Effect of magnesium ions and low pH on interaction of pyrimidine oligonucleotides with dsDNA: Affinity modification study. In Nucleic Acids Symposium Series 24: 107-111.
16. Alberts B, Johnson A, Lewis J et al. (2002) Molecular biology of the Cell. 4th (Edn.). New York: Garland Science; From RNA to Protein.
17. Kim MK, Lesoon-Wood LA, Weintraub BD et al. (1996) A soluble transcription factor, Oct-1, is also found in the insoluble nuclear matrix and possesses silencing activity in its alanine-rich domain. Molecular and Cellular Biology 16(8): 4366-4377.
18. Bear DG, Ng R, Van Derveer D et al. (1976) Alteration of polynucleotide secondary structure by ribosomal protein S1. Proceedings of the National Academy of Sciences 73(6): 1824-1828.
19. Prusoff WH, Mancini WR, Lin TS et al. (1984) Physical and biological consequences of incorporation of antiviral agents into virus DNA. Antiviral Research 4(6): 303-315.
20. Scherberg N and Refetoff S (1977) Iodination-deiodination: A radiochemical method for detection of structure and changes in structure in RNA. Biochimica et Biophysica Acta (BBA)-Nucleic Acids and Protein Synthesis 475(2): 337-351.